申请人:Norman Hurst Bryan
公开号:US20080064742A1
公开(公告)日:2008-03-13
The present invention relates to novel benzopyran ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory, bowel disease, and arthritis. Formula (I), wherein G is —O—, —S(O)—, —CF
2
—, —C(O)—, —CR
1
H— or —CR
2
(OH)—; R is halo, (C
1
-C
4
)alkyl or R
2
—(CH
2
)
m
—; R
1
is F, hydroxyl, cyano, trifluoromethyl, (C
1
-C
4
)alkyl, (C
2
-C
4
)alkenyl, (C
2
-C
4
)alkynyl, (C
1
-C
4
)alkoxy, (C
1
-C
4
)alkycarbonyloxy or benzyl; R
2
is trifluoromethyl or (C
1
-C
4
)alkyl; R
3
is cyano, hydroxyl, (C
2
-C
4
)alkenyl, (C
1
-C
4
)alkoxy or (C
1
-C
4
)alkoxycarbonyl; n is 0, 1 or 2; and m is 0, 1 or 2; and pharmaceutically acceptable salts thereof.
本发明涉及新型苯并吡喃ER-β激动剂化合物,其制备的药物组合物,以及使用这些化合物治疗ER-β介导的疾病,如夜尿症,梗阻性尿路病,良性前列腺增生,肥胖症,痴呆症,高血压,失禁,结肠癌,前列腺癌,不育,抑郁症,白血病,炎症性肠病和关节炎。其中,公式(I)中,G为—O—,—S(O)—,—CF2—,—C(O)—,—CR1H—或—CR2(OH)—;R为卤素,(C1-C4)烷基或R2—(CH2)m—;R1为F,羟基,氰基,三氟甲基,(C1-C4)烷基,(C2-C4)烯基,(C2-C4)炔基,(C1-C4)烷氧基,(C1-C4)烷基羧酸酯或苯甲基;R2为三氟甲基或(C1-C4)烷基;R3为氰基,羟基,(C2-C4)烯基,(C1-C4)烷氧基或(C1-C4)烷氧羰基;n为0,1或2;m为0,1或2;以及其药学上可接受的盐。